The global stem cell market is anticipated to expand at a CAGR of 9.50% during the forecast period of 2019-2027. The role of stem cells in the development of the regenerative medicine and treatment, and the important implementation of stem cell therapies for anti-aging and extending lifespan are contributing to the market growth for stem cell.
The global stem cell market is segmented on the basis of product, technology, application therapeutic, application, and treatment type, and geography. Safety issues and ethical issues have been limiting the growth for stem cell market. The safety issues regarding the storage of stem cells in the gene banks are required to be further clarified for reducing the immense exploitation of stem cell therapy. The growth in the stem cell applications market has been mostly influenced by the introduction of the regenerative medicines.
The stem cell market geography is segmented into North America, Europe, Asia-Pacific and the Rest of World. The stem cell market in North America is expected to hold the largest share by 2027. The rising number of the cancer cases in the region have mainly contributed to the growth of the market in the North American region. Asia Pacific is anticipated to grow with the fastest CAGR over the forecast period. The growth of the Asia Pacific region is primarily driven by the growing incidences of chronic lifestyle diseases, and the huge investments in medical research and healthcare facilities. On the other hand, the Europe stem cell analysis market is primarily driven by the rising prevalence of chronic disorders and the citizen’s changing lifestyles.
Corning Inc., Fibrocell Science Inc., Cytori Therapeutics, Brainstorm Cell Therapeutics, Thermo Fisher, Vericel Corporation (formerly Aastrom Bioscience), Becton Dickinson And Company, Takara Holdings Inc., Stryker Corporation, Biotime Inc., Cellular Engineering Technologies, Inc., StemCell Technologies, International Stem Cell Corp., Celgene Corporation, Cellular Dynamics International (Holding Company Fujifilm), GE Healthcare, Pluristem Therapeutics Inc., Qiagen N.V., and Stemedica Cell Technologies Inc. are the major companies operating in the market.